Esperion Therapeutics Inc (ESPR) Shares Sold by Alambic Investment Management L.P.

Alambic Investment Management L.P. decreased its holdings in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) by 33.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 6,707 shares of the biopharmaceutical company’s stock after selling 3,400 shares during the period. Alambic Investment Management L.P.’s holdings in Esperion Therapeutics were worth $442,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Meditor Group Ltd grew its stake in shares of Esperion Therapeutics by 1.2% during the fourth quarter. Meditor Group Ltd now owns 2,322,835 shares of the biopharmaceutical company’s stock worth $152,935,000 after acquiring an additional 27,900 shares during the last quarter. State Street Corp grew its stake in shares of Esperion Therapeutics by 264.6% during the second quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock worth $69,721,000 after acquiring an additional 1,093,292 shares during the last quarter. FMR LLC grew its stake in shares of Esperion Therapeutics by 2.3% during the second quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock worth $61,950,000 after acquiring an additional 30,000 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Esperion Therapeutics by 4.4% during the second quarter. Vanguard Group Inc. now owns 756,224 shares of the biopharmaceutical company’s stock worth $34,997,000 after acquiring an additional 32,074 shares during the last quarter. Finally, Pictet Asset Management Ltd. grew its stake in shares of Esperion Therapeutics by 12.3% during the third quarter. Pictet Asset Management Ltd. now owns 306,455 shares of the biopharmaceutical company’s stock worth $15,360,000 after acquiring an additional 33,574 shares during the last quarter. Institutional investors and hedge funds own 92.85% of the company’s stock.

ESPR has been the topic of a number of research analyst reports. Northland Securities restated a “buy” rating and set a $72.00 price target on shares of Esperion Therapeutics in a research note on Friday, November 10th. Chardan Capital restated a “neutral” rating and set a $75.00 price target (up previously from $20.00) on shares of Esperion Therapeutics in a research note on Tuesday, December 5th. BidaskClub lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Needham & Company LLC upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and boosted their price target for the stock from $72.00 to $81.00 in a research note on Thursday, December 14th. Finally, Bank of America upgraded Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price target on the stock in a research note on Friday, January 5th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $77.23.

In related news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the sale, the director now owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. 32.50% of the stock is owned by corporate insiders.

Shares of Esperion Therapeutics Inc (NASDAQ ESPR) opened at $67.15 on Friday. The company has a market capitalization of $1,730.00, a P/E ratio of -9.79 and a beta of 2.64. Esperion Therapeutics Inc has a 52-week low of $19.82 and a 52-week high of $82.18.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/09/esperion-therapeutics-inc-espr-shares-sold-by-alambic-investment-management-l-p.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply